Table 1.
Baseline patient demographics and disease characteristics
| Ruxolitinib (n=287) | Placebo (n=145) | Total (N=432) | ||
|---|---|---|---|---|
| Age, years | 56·4 (13·7; 22–90) | 56·9 (12·5; 20–84) | 56·5 (13·3; 20–90) | |
| Age category, ≥65 years | 83 (29%) | 39 (27%) | 122 (28%) | |
| Sex | ||||
| Female | 125 (44%) | 72 (50%) | 197 (46%) | |
| Male | 162 (56%) | 73 (50%) | 235 (54%) | |
| Race | ||||
| White | 242 (84%) | 109 (75%) | 351 (81%) | |
| American Indian or Alaska Native | 26 (9%) | 13 (9%) | 39 (9%) | |
| Black or African American | 6 (2%) | 9 (6%) | 15 (3%) | |
| Asian | 5 (2%) | 5 (3%) | 10 (2%) | |
| Multiple | 3 (1%) | 2 (1%) | 5 (1%) | |
| Unknown | 5 (2%) | 7 (5%) | 12 (3%) | |
| Ethnicity | ||||
| Hispanic or Latino | 93 (32%) | 39 (27%) | 132 (31%) | |
| Not Hispanic or Latino | 184 (64%) | 93 (64%) | 277 (64%) | |
| Not reported | 2 (1%) | 6 (4%) | 8 (2%) | |
| Unknown | 8 (3%) | 7 (5%) | 15 (3%) | |
| Weight, kg | 85·2 (18·8) | 87·2 (18·7) | 85·9 (18·8) | |
| n | 283 | 145 | 428 | |
| Body-mass index, kg/m2 | ||||
| n | 282 | 144 | 426 | |
| Mean (SD) | 29·9 (5·6) | 31·0 (6·5) | 30·3 (5·9) | |
| >30 kg/m2 | 129 (46%) | 72 (50%) | 201 (47%) | |
| Country | ||||
| Russia | 114 (40%) | 57 (39%) | 171 (40%) | |
| USA | 32 (11%) | 16 (11%) | 48 (11%) | |
| Brazil | 28 (10%) | 13 (9%) | 41 (9%) | |
| Spain | 29 (10%) | 10 (7%) | 39 (9%) | |
| Argentina | 16 (6%) | 11 (8%) | 27 (6%) | |
| Peru | 15 (5%) | 10 (7%) | 25 (6%) | |
| Turkey | 13 (5%) | 7 (5%) | 20 (5%) | |
| Mexico | 14 (5%) | 4 (3%) | 18 (4%) | |
| UK | 10 (3%) | 4 (3%) | 14 (3%) | |
| Colombia | 7 (2%) | 3 (2%) | 10 (2%) | |
| France | 4 (1%) | 6 (4%) | 10 (2%) | |
| Germany | 5 (2%) | 4 (3%) | 9 (2%) | |
| Time between onset of symptoms and randomisation, days | 11·0 (8·0–14·0) | 11·0 (8·0–13·5) | 11·0 (8·0–14·0) | |
| Time between diagnosis and randomisation, days | 5·0 (3·0–8·0) | 5·0 (3·0–7·0) | 5·0 (3·0–8·0) | |
| WHO (0–8) clinical status | ||||
| 3, hospitalised with mild disease (no oxygen therapy [defined as SpO2 ≥94% on room air]) | 94 (33%) | 47 (32%) | 141 (33%) | |
| 4, hospitalised with mild disease (oxygen by mask or nasal prongs) | 175 (61%) | 93 (64%) | 268 (62%) | |
| 5, hospitalised with severe disease (noninvasive ventilation or high-flow oxygen) | 17 (6%) | 5 (3%) | 22 (5%) | |
| Missing baseline clinical status | 1 (<1%) | 0 | 1 (<1%) | |
| Pneumonia | 284 (99%) | 144 (99%) | 428 (99%) | |
| Steroid use | 170 (59%) | 79 (54%) | 249 (58%) | |
| Remdesivir use | 21 (7%) | 7 (5%) | 28 (6%) | |
Data are mean (SD; range); n (%); mean (SD); n; or median (IQR). SpO2=oxygen saturation. WHO (0–8)=COVID-19-specific 9-point ordinal scale for clinical status proposed by WHO (appendix p 6).